SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Leifras Co., Ltd. Engages in sport training, event and alliance & club activity support and healthcare activities. It provides services related to the organization and operations of sports schools and sports events for children and it also operate a robust social business sector, dispatching sports coaches to meet various community needs. The company was founded by Kiyotaka Ito on August 28, 2001 and is headquartered in Tokyo, Japan.

Leifras Co Ltd - ADR

Leifras Co Ltd

Leifras Co Ltd ($LFS) is trending due to significant price movement, sparking excitement and FOMO among traders. Community discussions revolve around the potential for a short squeeze, with some comparing it to previous high-flying stocks and anticipating further gains, while others caution about a potential pump and dump.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending following positive Phase 3 results from Roche for a similar breast cancer drug, sparking speculation about OLMA's pipeline and potential analyst upgrades; the community is actively discussing price targets and short squeeze opportunities. Some traders are wary, pointing to the sympathy play aspect and potential for a pullback, while others see long-term potential and even buyout possibilities.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending following FDA approval of its drug Redemplo for familial chylomicronemia syndrome (FCS), sparking optimism about the company's pipeline and platform credibility. The community is highlighting Redemplo's less frequent dosing compared to competitors and anticipating a valuation reset, with some eyeing the stock's potential to reach new 52-week highs. This milestone is seen as a shift from clinical stage to commercial stage, potentially trapping shorts and attracting institutional investment.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors brace for its earnings report, with the community actively debating whether the company can meet high expectations amidst broader market concerns of an AI bubble. Discussions range from potential Saudi AI investment deals to the impact of institutional selling and the overall market's bearish sentiment, with many anticipating significant price movement post-earnings.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following strong Q3 earnings and partnerships, including Google; the community highlights the company's AI integration and potential to disrupt traditional banking. Discussions also focus on the company's growth in the U.S. market and the value of its data for targeted advertising. Some are concerned about Klarnas profitability and competition, as the stock hits new lows.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft's stock is drawing attention due to mixed sentiment around earnings and a new strategic partnership with Nvidia and Anthropic, which includes significant investments and compute capacity commitments. The community is debating whether these AI ventures will truly bolster Microsoft's financial performance or if they represent an overhyped bubble. Downgrades from analysts, citing concerns about profitability in the AI space, are also contributing to the discussion.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as the price of Bitcoin, a key asset for the company, experiences volatility, sparking debate about MicroStrategy's leveraged exposure and future prospects. Community discussions range from short-squeeze potential and bottom-fishing opportunities to concerns about debt and possible liquidation scenarios. Traders are actively monitoring technical levels and options activity to gauge near-term price movements.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending due to a mix of analyst downgrades citing AI spending concerns, and news of a potential partnership with Saudi-backed AI firm Humain; the community is debating whether these factors justify the recent price drop and impact on the stock's growth prospects, while some see it as a buying opportunity amid broader market volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as investors discuss a potential breakout and the company's upcoming presentation at the Inflammatory Skin Disease Summit. Community members are optimistic about the stock's potential, citing strong institutional ownership and a potentially positive FDA meeting in December. Some are speculating about a gamma squeeze, with bullish sentiment fueled by best-in-class data and a tight float.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending due to increased investor interest following recent developments, including a European contract win and the closing of the Sentrycs acquisition; however, discussions are centered around a potential share dilution as shareholders prepare to vote on increasing authorized shares, leading to concerns and debates about the company's financial strategy and future valuation. Despite dilution concerns, community members highlight the company's increasing contracts and long-term potential in the drone and autonomous systems market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Olema’s lead product candidate, Palazestrant, belongs to the same class of drugs as Roche’s and is being studied in breast cancer.&nbsp;</li><li>Oppenheimer raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.&nbsp;</li><li>The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.</li></ul>Shares of Olema Pharmaceuticals Inc. (OLMA) more than doubled Tuesday morning on the heels of Roche announcing positive results from its late-stage trial in breast cancer.Roche was <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.roche.com/media/releases/med-cor-2025-11-18">evaluating</a> Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. In the study, Giredestrant treatment showed a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard-of-care endocrine therapy.Giredestrant is an investigational, oral, selective oestrogen receptor degrader or SERD. According to Roche, this is the first late-stage study of a SERD to demonstrate a significant benefit in the adjuvant setting.<h2 class="st-heading-2">Expert Take</h2>As per Oppenheimer, Olema shares were trading pre-market on news that Roche's (RHHBY) trial met its primary endpoint. The analyst subsequently raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.Oppenheimer said it was not expecting this readout, as the entire narrative has been around Roche's different breast cancer clinical trials. Nonetheless, the data are a welcome surprise, it added.Early breast cancer is a multi-billion-dollar market, and one that the firm did not have in its model. These data also incrementally derisk another Roche drug trial, which is testing oral SERDS against aromatase inhibitors in the frontline metastatic setting, Oppenheimer added.Olema’s lead product candidate, Palazestrant, is also a SERD being investigated in patients with recurrent, locally advanced, or metastatic forms of breast cancer. It is being evaluated as a single agent in a late-stage trial and in combination with ribociclib in another late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OLMA">OLMA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/59;" src="data:image/png;base64,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" width="622" height="59" alt="OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits"><figcaption>OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed pessimism about the stock, noting that the hype had passed by pre-market hours, when the stock was up over 200%.<stembedurl>https://stocktwits.com/ChannelRed/message/636586904</stembedurl>Another user, however, believes the stock will touch $100.<stembedurl>https://stocktwits.com/murphylaw/message/636586451</stembedurl>OLMA stock is up by 233% this year and by 125% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-shifts-to-royalty-driven-model-approves-125-m-buyback-plan/cLPVdKtRE7F">Zymeworks Shifts To Royalty-Driven Model From Licensed Drugs, Approves $125M Buyback Plan</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Equity

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.


Olema Pharmaceuticals, Inc. $OLMA Holdings Raised by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 153.8% during the 2nd quarter, according to its most recent disclosure...

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6.3% - Time to Buy?

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Here's Why...

Analysts Set Expectations for OLMA FY2025 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Research analysts at HC Wainwright issued their FY2025 EPS estimates for shares of Olema Pharmaceuticals in a report released on Tuesday...

FY2025 Earnings Estimate for OLMA Issued By Lifesci Capital

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at Lifesci Capital reduced their FY2025 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to...

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 7.2% After Earnings Miss

Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 7.2% After Earnings Miss...

Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.05 EPS

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) released its earnings results on Monday. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05...

OLMA Stock Soars 47% in September So Far on Second PFE Deal

Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.

Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent...

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

OLMA
Olema Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OLMA News

OLMAOlema Pharmaceuticals Inc